Neuphoria Therapeutics to Merge With Scancell; Holders to Receive ADSs Plus CVRs
Neuphoria Therapeutics signed a definitive merger agreement with Scancell under which each Neuphoria share will convert into Scancell ADSs plus one CVR, targeting post-close ownership of about 11.1% for Neuphoria holders. Closing is subject to shareholder approvals, Nasdaq listing of Scancell ADSs…